6127.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 10:08):

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally...

Stats
Dagens volum	1.06M
Gjennomsnittsvolum	1.40M
Markedsverdi	12.61B
EPS	HKD0.270 ( 2024-01-10 )
Last Dividend	HKD0.440 ( 2023-06-20 )
Next Dividend	HKD0 ( N/A )
P/E	16.98
ATR14	HKD0.0180 (0.19%)

Volum Korrelasjon

Lang: 0.14 (neutral)

Kort: 0.57 (weak)

Signal:(70.029) Neutral

Joinn Laboratories Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Joinn Laboratories Korrelasjon - Valuta/Råvare

0.35
( neutral )

0.50
( neutral )

0.00
( neutral )

-0.24
( neutral )

-0.19
( neutral )

-0.16
( neutral )

Joinn Laboratories Økonomi

Annual	2023
Omsetning:	HKD2.38B
Bruttogevinst:	HKD1.01B (42.62 %)
EPS:	HKD0.530

FY	2023
Omsetning:	HKD2.38B
Bruttogevinst:	HKD1.01B (42.62 %)
EPS:	HKD0.530

FY	2022
Omsetning:	HKD2.27B
Bruttogevinst:	HKD1.09B (47.90 %)
EPS:	HKD2.01

FY	2021
Omsetning:	HKD1.52B
Bruttogevinst:	HKD739.12M (48.73 %)
EPS:	HKD1.255

Financial Reports:

No articles found.

Joinn Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.420 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.440 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Joinn Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.32 - Stable (13.66%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.214	2021-06-23
Last Dividend	HKD0.440	2023-06-20
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD1.074	--
Avg. Dividend % Per Year	0.00%	--
Score	2.85	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.32
Div. Directional Score	7.74	--

Next Divdend (Est)
(2025-05-12)

HKD0.460 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.85

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6939.HK	Ex Dividend Knight	2023-06-14	Annually	0.00%
1983.HK	Ex Dividend Junior	2023-10-17	Sporadic	0.00%
1052.HK	Ex Dividend Junior	2023-11-03	Annually	0.00%
0133.HK	Ex Dividend Junior	2023-06-01	Annually	0.00%
3600.HK	Ex Dividend Knight	2023-09-12	Annually	0.00%
1600.HK	Ex Dividend Knight	2023-10-24	Semi-Annually	0.00%
0656.HK	Ex Dividend Junior	2023-06-14	Annually	0.00%
9979.HK	Ex Dividend Knight	2023-07-11	Semi-Annually	0.00%
2189.HK	Ex Dividend Knight	2023-08-16	Semi-Annually	0.00%
1186.HK	Ex Dividend Junior	2023-07-25	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.167	1.500	6.66	9.99	[0 - 0.5]
returnOnAssetsTTM	0.0396	1.200	8.68	10.00	[0 - 0.3]
returnOnEquityTTM	0.0483	1.500	-0.575	-0.862	[0.1 - 1]
payoutRatioTTM	0.540	-1.000	4.60	-4.60	[0 - 1]
currentRatioTTM	4.85	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.52	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.951	1.500	0.272	0.408	[0.2 - 2]
debtRatioTTM	0.00692	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	5 875.11	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	1.081	2.00	9.64	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.828	2.00	9.59	10.00	[0 - 20]
debtEquityRatioTTM	0.00839	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.426	1.000	6.23	6.23	[0.2 - 0.8]
operatingProfitMarginTTM	0.213	1.000	7.73	7.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	11.87	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.237	0.800	-1.753	-1.403	[0.5 - 2]
Total Score				11.17

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.20	1.000	8.36	0	[1 - 100]
returnOnEquityTTM	0.0483	2.50	-0.369	-0.862	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.828	2.00	9.72	10.00	[0 - 30]
dividendYielPercentageTTM	4.91	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.081	2.00	9.64	10.00	[0 - 30]
payoutRatioTTM	0.540	1.500	4.60	-4.60	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.347	1.000	3.83	0	[0.1 - 0.5]
Total Score				4.32

Joinn Laboratories

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.